Results 1 to 10 of about 24,341 (292)

Pediatric Atypical Hemolytic Uremic Syndrome Advances [PDF]

Cells, 2021
Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterized by dysregulation of the alternate pathway. The diagnosis of aHUS is one of exclusion, which complicates its early detection and corresponding intervention to mitigate its high ...
Rupesh Raina, Nina Vijayvargiya, Amrit Khooblall, Manasa Melachuri, Shweta Deshpande, Divya Sharma, Kashin Mathur, Manav Arora, Sidharth Kumar Sethi, Sonia Sandhu   +9 more
doaj   +4 more sources

COVID-19 vaccination and Atypical hemolytic uremic syndrome

Frontiers in Immunology, 2022
IntroductionCOVID-19 vaccination has been associated with rare but severe complications characterized by thrombosis and thrombocytopenia.Methods and ResultsHere we present three patients who developed de novo or relapse atypical hemolytic uremic syndrome
Romy N. Bouwmeester, Esther M.G. Bormans, Caroline Duineveld, Arjan D. van Zuilen, Anne-Els van de Logt, Jack F.M. Wetzels, Nicole C.A.J. van de Kar   +6 more
doaj   +7 more sources

A novel missense mutation in complement factor I predisposes patients to atypical hemolytic uremic syndrome: a case report

Journal of Medical Case Reports, 2022
Background Atypical hemolytic uremic syndrome, also called the nondiarrheal form of hemolytic uremic syndrome, is a rare disease characterized by the triad of thrombocytopenia, Coomb’s test-negative microangiopathic hemolytic anemia, and acute renal ...
Xin Wei, Juan Li, Xiaojiang Zhan, Luxia Tu, Haowen Huang, Ying Wang   +5 more
doaj   +2 more sources

Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

Frontiers in Immunology, 2022
Atypical hemolytic uremic syndrome (aHUS), also called complement-mediated hemolytic uremic syndrome (CM-HUS), is a rare disease caused by dysregulation in the alternative complement activation pathway. It is a life-threatening condition causing ischemia
Romana Rysava, Martina Peiskerova, Vladimir Tesar, Jan Benes, Jan Benes, Martin Kment, Ágnes Szilágyi, Ágnes Szilágyi, Dorottya Csuka, Dorottya Csuka, Zoltán Prohászka, Zoltán Prohászka   +11 more
doaj   +2 more sources

Complement activation in atypical hemolytic uremic syndrome and scleroderma renal crisis: a critical analysis of pathophysiology [PDF]

Brazilian Journal of Nephrology, 2018
Scleroderma is an autoimmune disease that affects multiple systems. While pathophysiologic mechanisms governing the development of scleroderma are relatively poorly understood, advances in our understanding of the complement system are clarifying the ...
Roman Zuckerman, Arif Asif, Eric J. Costanzo, Tushar Vachharajani   +3 more
doaj   +4 more sources

Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease [PDF]

Thrombosis Journal, 2019
Background Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle.
Ramy M. Hanna, Noah Merin, Richard M. Burwick, Lama Abdelnour, Umut Selamet, Beshoy Yanny, Patrick Bui, Mary Fouad, Ira Kurtz   +8 more
doaj   +3 more sources

Atypical hemolytic uremic syndrome in a child: A rare case report [PDF]

Clinical Case Reports
Key Clinical Message Atypical hemolytic uremic syndrome, a rare thrombotic microangiopathy, necessitates early diagnosis and comprehensive care due to its potential severity, emphasizing the importance of a multidisciplinary approach to improve outcomes.
Bishal Kunwor, Bishal Sharma, Suchit Thapa Chhetri, Prerana Joshi, Dipendra Pradhan   +4 more
doaj   +2 more sources

Atypical Hemolytic Uremic Syndrome Precipitated by Recurrent Pancreatitis

Annals of Internal Medicine: Clinical Cases, 2022
Atypical hemolytic uremic syndrome presents with negative direct antiglobulin test microangiopathic hemolytic anemia, acute kidney injury, and thrombocytopenia in the absence of diarrhea.
Nivine El-Hor, Kyle Kondrat, Suresh Balasubramanian   +2 more
doaj   +1 more source

Clostridioides difficile-Associated Atypical Hemolytic-Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review

Critical Care Explorations, 2021
BACKGROUND:. Clostridioides difficile infection is a rare precipitant for patients to develop atypical hemolytic-uremic syndrome, of which the pathogenesis remains unclear. Previous reports suggest activation of cytokine storm from binding of cyotoxins A
Michael N. Moulton, DO, Carl L. Kay, MD, Joshua T. Romain, MD, Benjamin D. Morrow, MD, Gilda M. Bobele, MD   +4 more
doaj   +1 more source

Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future

Pediatric Drugs, 2023
Atypical hemolytic uremic syndrome is a thrombotic microangiopathy characterized by hemolysis, thrombocytopenia, and acute kidney injury, usually caused by alternative complement system overactivation due to pathogenic genetic variants or antibodies to ...
Evgenia Gurevich, D. Landau
semanticscholar   +1 more source